Literature DB >> 8093733

Cisapride and 5-hydroxytryptamine enhance motility in the canine antrum via separate pathways, not involving 5-hydroxytryptamine1,2,3,4 receptors.

W J de Ridder1, J A Schuurkes.   

Abstract

Prokinetic benzamides (e.g., cisapride) enhance gastrointestinal motility and transit. In vitro studies on the guinea pig ileum suggest that their effect is mediated via serotonergic 5-hydroxytryptamine (5-HT4) receptors, resulting in a facilitation of cholinergic neurotransmission. However, most in vivo studies have been performed on the canine stomach. Therefore, our aim was to determine whether the findings obtained on the guinea pig ileum can be extrapolated to another species and another organ. Does a benzamide facilitate cholinergic neutrotransmission on strips of the canine stomach in vitro? If so, does the benzamide exert its effect via a serotonergic 5-HT4 mechanism? Longitudinal muscle strips with adhering myenteric plexus were isolated from the canine stomach and were electrically stimulated at submaximal frequencies resulting in a mean contractile response of 16 +/- 7% of the response to methacholine (10(-6) M). Atropine and tetrodotoxin (both 3 x 10(-7) M) abolished the contractile responses, whereas hexamethonium (10(-4) M) had no effect. Cisapride (3 x 10(-7) M) enhanced the contractile responses from 14 to 70% (59 +/- 5% increase). 5-HT (3 x 10(-7) M) similarly enhanced the responses from 12 to 72% (58 +/- 5% increase). Cisapride induced a sustained enhancement throughout the duration of the experiment; in contrast, the effect of 5-HT subsided in about 90 min. Single-concentration administration of cisapride (10(-8)-10(-6) M) and 5-HT (10(-9)-3 x 10(-7) M) resulted in EC50 values of 1.0 (0.8-1.4) x 10(-7) M for cisapride and 1.3 (0.8-2.1) x 10(-8) M for 5-HT. Methiothepin and methysergide (both 3 x 10(-7) M; 5-HT1-receptor antagonists), ketanserin and LY 53857 (both 3 x 10(-7) M; 5-HT2-receptor antagonists), granisetron (3 x 10(-7) M; 5-HT3-receptor antagonist) or ICS 205-930 (3 x 10(-7) M; 5-HT3-receptor antagonist and in addition 5-HT4-receptor antagonist at 3 x 10(-6) M) did not reduce the responses to both cisapride and 5-HT. 1-(1-Naphthalenyl)piperazine (10(-6) M; 5-HT-receptor antagonist in the rat gastric fundus) significantly reduced the increase by 5-HT (24 +/- 7%; 7-31%) but had no effect on the cisapride (3 x 10(-7) M)-induced increase (69 +/- 4%; 8-77%).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093733

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle.

Authors:  N H Prins; J F Van Haselen; R A Lefebvre; M R Briejer; L M Akkermans; J A Schuurkes
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 2.  Receptors of the enteric nervous system: potential targets for drug therapy.

Authors:  J Tack
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

3.  5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study.

Authors:  N H Prins; A van Der Grijn; R A Lefebvre; L M Akkermans; J A Schuurkes
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle.

Authors:  N H Prins; L M Akkermans; R A Lefebvre; J A Schuurkes
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 5.  A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders.

Authors:  J Tack; G Coremans; J Janssens
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

6.  Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors.

Authors:  C A Rizzi; A Sagrada; A Schiavone; P Schiantarelli; R Cesana; G B Schiavi; H Ladinsky; A Donetti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-04       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.